https://www.selleckchem.com/pr....oducts/itacitinib-in
Radiological improvement, defined as reduced T2/fluid-attenuated inversion recovery signal and mass effect, was observed in 50% of patients; however, this did not completely overlap with clinical response. Both early and late radiation necrosis responded equally well to bevacizumab therapy. Overall, bevacizumab was very well tolerated, permitting a reduction of corticosteroid dose and/or duration in the majority of patients. Bevacizumab appears to be effective and well-tolerated in children as treatment for symptomatic radi
Like
Comment
Share
